Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

NCT07477366 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed B-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: CD19 t-haNK- IV Administration
DRUG: N-803
DRUG: rituximab

Sponsor

ImmunityBio, Inc.